Trending Now - RFK Jr. Challenges FDA on Peptides, Impacting Hims & Hers
WHO:
CNBC - HHS Secretary Robert F. Kennedy Jr. announced the FDA's plans.
CNBC - Andrew Dudum is the CEO of Hims & Hers Health.
CNBC - Dr. Patrick Carroll is the Chief Medical Officer of Hims & Hers Health.
CNBC - Michael Cherny is an analyst at Leerink Partners.
WHAT:
CNBC - Hims & Hers Health's shares jumped to around $26 a share on April 15th, 2026, following the announcement by Kennedy.
CNBC - Leerink Partners has a hold-equivalent rating on Hims & Hers stock with a price target of $25.
CNBC - Of the dozen peptides listed by Kennedy for consideration, one, MK-677, is often treated as an illegal drug when sold for human consumption and has been banned by the World Anti-Doping Agency.
CNBC - The FDA plans to convene a Pharmacy Compounding Advisory Committee meeting to review peptides for potential inclusion on the 503A bulk list.
CNBC - Hims & Hers Health's shares jumped following the announcement on April 15th, 2026.
CNBC - Hims & Hers made a significant move into the peptide space in February 2025 by acquiring a California-based peptide facility.
CNBC - Leerink Partners stated that the FDA's review of peptides could provide Hims with a clearer regulatory path to scale peptide therapies.
CNBC - The stock price of Hims & Hers was trading around $26 a share on April 15th, 2026.
WHERE:
CNBC - The peptide facility acquired by Hims & Hers is located in California.
WHEN:
CNBC - The FDA meeting to review peptides is scheduled for July 2026.
CNBC - Hims & Hers acquired the peptide facility in February 2025.
CNBC - The announcement by Kennedy was made on April 15th, 2026.
WHY:
CNBC - Kennedy argued that the Biden administration restricted the use of peptides due to safety concerns that he considers unfounded.
CNBC - The review of peptides is intended to bring peptide therapy into regulated, physician-led care.
CNBC - Kennedy argued that the Biden administration restricted the use of peptides due to unfounded safety concerns.
HOW:
CNBC - The FDA's review process for peptides is just beginning, and the July meeting will be advisory only, indicating that changes are not expected to be immediate.
CNBC - Peptides are being explored for a wide range of health and wellness uses, but their production remains largely unregulated.
CNBC - Hims & Hers is directing members toward branded rather than more profitable compounded GLP-1 drugs as part of its strategy.
(UPDATED April 16, 2026 23:15 UTC)
Shares of Hims & Hers Health surged to around $26 each on Wednesday, following a significant announcement by Kennedy. Leerink Partners has placed a hold-equivalent rating on the stock with a price target of $25, while Kennedy highlighted MK-677 as one of the peptides under consideration, despite its classification as an illegal drug for human consumption. The FDA's review process for peptides is just getting underway, with an advisory meeting scheduled for July, suggesting that any changes to regulations may not happen right away.
--
(UPDATED April 16, 2026 19:24 UTC)
HHS Secretary Robert F. Kennedy Jr. announced that the FDA plans to hold a Pharmacy Compounding Advisory Committee meeting in July 20th26 to review peptides for potential inclusion on the 503A bulk list. Following this announcement on Wednesday, shares of Hims & Hers Health surged, trading around $26, as the company had previously made a significant move into the peptide space by acquiring a California-based facility in February 20th25. The FDA's review aims to bring peptide therapy into regulated, physician-led care, addressing concerns that the Biden administration had restricted their use due to unfounded safety issues.